EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

EpiVax-Guilhem

More Like This

PR Newswire associated0

EpiVax Drives Immunogenicity Innovation in 2024: Year in Review

PR Newswire associated0

EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO

PR Newswire associated0

Novel Immunogenicity Risk Assessment Platform, ISPRI, Facilitates Biologic Therapeutics Development

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

PR Newswire associated0

EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs

New and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be Presented

PR Newswire associated0

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

PR Newswire associated0

Viva Biotech Launches the AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery